证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-075 丽珠医药集团股份有限公司 医保支付标准、医保报销细则等相关信息需以国家医保局等相关部门公示的 信息为准。本公司产品未来销售情况受医药行业政策变动、市场环境变化等影响， 具有一定的不确定性。敬请广大投资者审慎决策，注意投资风险。 特此公告。 关于公司产品纳入国家医保目录的公告 丽珠医药集团股份有限公司董事会 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年本集团共有 194 个产品纳入《国家医保目录》，含甲类 92 个、乙类 102 个。其中：注射用阿立哌唑微球通过谈判首次纳入国家医保目录，注射用醋 酸曲普瑞林微球新增适应症，注射用艾普拉唑钠续约成功，具体详情如下： | 药品名称 | 剂型 | 限定支付范围 | 首次获批 上市时间 | | 谈判情形 | | --- | --- | --- | --- | --- | --- | | 注射用阿立 哌唑微球 | 注射剂 | 无 | 年 2025 | 月 4 | 首次纳入 | | 注射用醋酸 曲普瑞林微 | 注射剂 ...

Core Viewpoint - The announcement by the company indicates that three of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory, which is expected to positively impact future performance [1] Group 1: Product Inclusion - The company has three products included in the new drug directory: injectable aripiprazole microspheres, which is included for the first time; injectable triptorelin acetate microspheres, which has a new indication; and injectable esomeprazole sodium, which has successfully renewed its contract [1] - No products from the company have been removed from the directory, indicating a stable product portfolio [1] Group 2: Market Impact - The inclusion of these products is expected to expand market reach and improve drug accessibility, which will likely have a positive effect on the company's future performance [1] - The new directory will be implemented on January 1, 2026, and is not expected to have a significant impact on the current period's performance [1]

Core Viewpoint - Lijun Group (000513.SZ) announced that it has 194 products included in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's operating performance in the future [1] Group 1: Product Inclusion - The group has 194 products in the National Medical Insurance Directory, including 92 Class A and 102 Class B products [1] - The injectable aripiprazole microsphere has been included in the National Medical Insurance Directory for the first time through negotiations [1] - The injectable triptorelin acetate microsphere has a new indication added, and the injectable esomeprazole sodium has successfully renewed its contract [1] - No products from the group have exited the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of these products in the National Medical Insurance Directory is expected to help expand the market and improve drug accessibility [1] - The new version of the National Medical Insurance Directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1]

Group 1 - The company held its 29th meeting of the 11th Board of Directors on December 5, 2025, via telecommunication voting, with all 11 directors present, complying with relevant laws and regulations [1] - The Board approved an adjustment to the expected related party transactions for 2025 with its subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd., increasing the total expected amount to RMB 166 million, with an additional RMB 37.6 million [2] - The expected amount for energy services was adjusted from RMB 11.8 million to RMB 16 million, and for other labor services from RMB 11.6 million to RMB 45 million, while the amounts for procurement and leasing remained unchanged [2] Group 2 - The proposal involves related party transactions as Health元药业集团股份有限公司 holds a 22.58% stake in Lizhu Monoclonal Antibody, with certain directors abstaining from voting due to conflicts of interest [3] - The proposal was reviewed and approved by the independent directors in a special meeting, with unanimous consent from all independent directors [4] - The voting results showed 7 votes in favor, 0 against, and 0 abstentions [5]

每经AI快讯，丽珠集团（SZ 000513，收盘价：35.78元）12月5日晚间发布公告称，公司第十一届第二 十九次董事会会议于2025年12月5日以通讯表决的方式召开。会议审议了《关于调整公司与丽珠单抗 2025年度持续关连交易预计的议案》等文件。 2025年1至6月份，丽珠集团的营业收入构成为：医药制造业占比100.0%。 截至发稿，丽珠集团市值为323亿元。 每经头条（nbdtoutiao）——秒光、售罄！银行大额存单成稀缺资源，2%以上产品很难抢，有的门槛高 达1000万元！专家：存款利率或长期下行 （记者 曾健辉） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 持續關連交易 與麗珠單抗訂立二零二五水電補充協議及二零二五勞務服務 補充協議 與麗珠單抗訂立二零二五水電補充協議及二零二五勞務服務補充協議 2025年12月5日，為了滿足麗珠單抗經營發展需要，本公司召開董事會審議批准調整自 2025年1月1日起計至2025年12月31日止期間內本集團向麗珠單抗提供水、電、蒸汽及 污水處理之持續關連交易的年度上限，最高金額從人民幣11.80百萬元調整為人民幣 16.00百萬元；本集團向麗珠單抗提供勞務服務之持續關連交易的額度，最高金額從人 民幣11.60百萬元調整為人民幣45.00百萬元。同日，本公司與麗珠單抗就上述持續關連 交易訂立了二零二五水電補充協議及二零二五勞務服務補充協議，分別與2024年12月31 日訂立的現有二零二五水電框架協議及現有二零二五勞務服務框架協議構成不可分割的 一部分。 《香港上市規則》的涵義 於本公告日期，健康元直接及間接擁有本公司約46.33 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-074 丽珠医药集团股份有限公司 第十一届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 丽珠医药集团股份有限公司（以下简称"公司"）第十一届董事会第二十九 次会议于 2025 年 12 月 5 日以通讯表决的方式召开，会议通知已于 2025 年 11 月 30 日以电子邮件形式发送。本次会议应参会董事 11 人，实际参会董事 11 人， 本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定。 经与会非关连董事认真审议，一致同意根据公司业务实际开展情况，就与控 股子公司珠海市丽珠单抗生物技术有限公司（以下简称"丽珠单抗"）2025 年度 发生的包括提供水电等能源、提供劳务服务以及租出资产等持续关连交易的预计 金额进行调整，调整后的金额为人民币 16,600 万元，新增金额为人民币 3,760 万元。其中，提供水电等能源服务的预计额由原人民币 1,180 万元调整为人民币 1,600 万元；提供其他 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《第十一屆董事會第二 十九次會議決議公告》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* 公司秘書 二零二五年十二月五日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先 生 ; 而本公司的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗 婕女士。 第十一届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 劉寧 中國，珠 ...

持續關連交易 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 與麗珠單抗訂立二零二五水電補充協議及二零二五勞務服務 補充協議 與麗珠單抗訂立二零二五水電補充協議及二零二五勞務服務補充協議 2025年12月5日，為了滿足麗珠單抗經營發展需要，本公司召開董事會審議批准調整自 2025年1月1日起計至2025年12月31日止期間內本集團向麗珠單抗提供水、電、蒸汽及 污水處理之持續關連交易的年度上限，最高金額從人民幣11.80百萬元調整為人民幣 16.00百萬元；本集團向麗珠單抗提供勞務服務之持續關連交易的額度，最高金額從人 民幣11.60百萬元調整為人民幣45.00百萬元。同日，本公司與麗珠單抗就上述持續關連 交易訂立了二零二五水電補充協議及二零二五勞務服務補充協議，分別與2024年12月31 日訂立的現有二零二五水電框架協議及現有二零二五勞務服務框架協議構成不可分割的 一部分。 《香港上市規則》的涵義 於本公告日期，健康元直接及間接擁有本公司約46.33 ...

Core Points - The Medical Health R Index (480016) closed at 7284.72 points, down 0.42%, with a trading volume of 17.046 billion yuan and a turnover rate of 0.61% [1] - Among the index constituents, 23 stocks rose while 26 fell, with TeBao Bio leading the gainers at 2.85% and Renfu Pharmaceutical leading the decliners at 3.33% [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.66%, latest price at 87.62, down 2.01%, and a market cap of 261.437 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 11.00%, latest price at 60.97, down 0.25%, and a market cap of 404.670 billion yuan [1] - Mindray Medical (sz300760) with a weight of 7.57%, latest price at 199.50, down 0.56%, and a market cap of 241.882 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.27%, latest price at 128.88, up 0.13%, and a market cap of 106.217 billion yuan [1] - Pianzai Shou (sh600436) with a weight of 3.48%, latest price at 171.48, up 1.33%, and a market cap of 103.457 billion yuan [1] - Aier Eye Hospital (sz300015) with a weight of 3.42%, latest price at 11.35, down 1.30%, and a market cap of 105.843 billion yuan [1] - Kelun Pharmaceutical (sz002422) with a weight of 2.59%, latest price at 34.00, down 0.03%, and a market cap of 54.334 billion yuan [1] - Xinhecheng (sz002001) with a weight of 2.42%, latest price at 24.44, up 0.20%, and a market cap of 75.114 billion yuan [1] - Fosun Pharma (sh600196) with a weight of 2.39%, latest price at 27.05, down 0.15%, and a market cap of 72.235 billion yuan [1] - Ziji Shenzhou (sh688235) with a weight of 2.27%, latest price at 275.20, down 1.59%, and a market cap of 423.995 billion yuan [1] Capital Flow Analysis - The Medical Health R Index constituents experienced a net outflow of 1.159 billion yuan from institutional investors, while retail investors saw a net inflow of 999 million yuan [1] - Detailed capital flow for specific stocks shows: - Health元 (600380) had a net inflow of 34.2431 million yuan from institutional investors [2] - Hengrui Medicine (600276) had a net inflow of 29.9909 million yuan from institutional investors [2] - Long Spring High-tech (000661) had a net inflow of 19.8154 million yuan from institutional investors [2] - The index constituents underwent adjustments, adding four new stocks and removing one [2]